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differences in health related quality of life but the duplex surveillance
program was more costly by an average of 495 pounds more per patient.
Comment: Vein graft stenoses develop more frequently in longer
grafts (ie tibial distal targets), grafts placed for limb salvage, disadvantaged
grafts (composite grafts, arm vein grafts) and perhaps in patients undergoing
repeat procedures. In this paper most of the patients probably had primary
operations as evidenced by the high level of use of ipsilateral greater
saphenous vein, 2/3 of the anastomoses were to the popliteal artery, and
amputation rates appeared to have been analyzed using both claudicants and
limb salvage patients for the life table, a bit of a no-no. In short, if ever there
were a group of patients who are unlikely to benefit from duplex surveillance,
this is the group. This paper should not lead one to abandon vascular
laboratory duplex surveillance for vein grafts potentially at increased risk for
stenosis as noted above. However, the data does suggest that when a vein
graft is placed to a popliteal artery using ipsilateral saphenous vein, duplex
surveillance may not be of much benefit in reducing amputations over the
short run.
Suboptimal Intensity of Risk Factor Modification in Peripheral Arterial
Disease (PAD)
Oka RK, Umoh E, Szuba A, et al. Vasc Med 2005;10:91-6.
Conclusion: There is suboptimal medical management of atheroscle-
rotic risk factors in patients with peripheral arterial disease (PAD).
Summary: The PARTNERS study (PAD Awareness, Risk and Treat-
ment) indicated that PADwas under recognized in primary care practice and
only 60% of patients with PADwere receiving lipid lowering therapy (JAMA
2001;286:1317-24). This study sought to determine if practice guidelines
for patients with cardiovascular disease, developed after publication of
PARTNERS, have effected current community management of PAD.
The authors recruited via a media campaign conducted in a large
northern California urban area patients with leg pain that limited their
walking. Respondents were screened by telephone and, if eligible, offered
PAD assessment. Eligibility criteria included age 50 years with symptom-
atic PAD. PAD was defined as exertional leg pain with an ankle brachial
index 0.9. For patients with diabetes, PAD was defined as a toe pressure
of30mmHg. Patients must have been able to walk for 2minutes or 50 feet
on an exercise treadmill and have been on a stable medication regimen.
Patients with rest pain, ulceration or gangrene were excluded. Also excluded
were patients with recent myocardial infarction, Type I diabetes, and active
malignancy. Treatment and risk factor profiles were determined by self
reported medical history and current medication lists. Patients were
evaluated as to whether or not they met current treatment guidelines for
lipids, hypertension, and diabetes. With respect to lipids, an LDL cho-
lesterol 100 mg/dl was considered to have met therapeutic guidelines.
Hypertension was defined as a systolic blood pressure140 mmHg and a
diastolic blood pressure 90 mmHg. Hemoglobin A1c levels (HgbA1c)
7% indicated suboptimal glycemic control.
There were 101 subjects in this study. Dyslipidemia was recognized in
56.4%. In dyslipidemic subjects there was suboptimal therapy in 52.6%. In
addition, 20.8% of the sample were previously unrecognized cases.
A history of hypertension was reported in 54.5% of the study sample.
Management of systolic blood pressure was sub-optimal in 74.5% of hyper-
tensive subjects. Systolic hypertension had been previously unrecognized in
13.9% of the study subjects. Hypertensive patients were found a 81%
utilization rate of antihypertensive medication. Patients on mono versus
triple therapy for hypertension exhibited no significant differences in systolic
or diastolic blood pressures.
Diabetes was reported in 26.7% of the patients. HgbA1c was 7.9 1.9
mg/dl. Glycemic control was felt to be suboptimal in 57% of patients (mean
HgbA1c  8.7  1.8 mg/dl).
Sixty-two percent of the study population was on anti-platelet therapy.
Anticoagulation therapy was employed in 15%. About 35% of subjects (n 
36) were not taking anticoagulant or anti-platelet therapy. No patients
appeared to have had a contraindication to anti-platelet therapy.
Comment: The study is small and therefore subject to Type II
statistical error. Nevertheless, the results are similar to PARTNERS and
indicate suboptimal management of risk factors in patients with PAD. It
is clear one publication, the PARTNERS publication, has not had a
dramatic impact on primary care practice with respect to management of
PAD. Meaningful changes in management of PAD risk factors will only
occur after intensive promulgation of treatment goals for patients with
PAD.
Use of Quantitative Magnetic Resonance Angiography to Stratify
Stroke Risk in Symptomatic Vertebrobasilar Disease
Amin-Hanjani S, Du X, Zhao M, et al. Stroke 2005;36:1140-5.
Conclusion: Quantitative magnetic resonance angiography (QMRA)
can stratify risk for stroke in patients with symptomatic vertebrobasilar
disease (VBD).
Summary: Phase-contrast QMRA is a magnetic resonance technique
for noninvasively measuring blood flow in intracranial vessels (Magn Reson
Imaging 2000;18:697-706). The authors used a standard protocol that
included QMRA to evaluate patients with symptomatic VBD. QMRA was
used to stratify patients according to the presence or absence of flow
compromise distal to the site of VBD. Flow was considered compromised in
specific vessels if it was reduced greater than 20% of the lower limit of normal
baseline value for that vessel. Flow compromise was evaluated in the basilar
and posterior cerebral arteries. The basilar artery was designated as having
reduced flow if flow measurements were less than 12 mL/min, and the
posterior cerebral arteries were designated as having reduced flow if flow
measurements were less than 40 mL/min. Patients with low distal flows
were then offered either surgical or endovascular intervention, and other
patients received standard medical therapy. The article reports the results of
this protocol for patients treated from 1998 to 2003. There were 50 patients
subjected to the protocol and 47 available for follow-up over a mean interval
of 28 months. Kaplan-Meier curves were used to calculate stroke and
stroke-free survival at 2 years and a combination of stroke-free survival and
freedom from transient ischemic attacks at 2 years.
Patients with normal distal flow (n  31) had event-free survivals of
100% and 96%, respectively. At 2 years patients with low distal flows had a
71% event-free survival with respect to stroke and a 53% event-free survival
with respect to the combined end point of stroke and transient ischemic
attack. Patients with low distal flows had a higher risk of recurrent ischemia
(P  .003). Twelve patients with low flow underwent treatment and had
82% event-free survival. With Cox proportional analysis, flow status effected
event-free survival independently of covariants.
Comment: Patients with symptomatic VBD can be offered interven-
tion for large-vessel stenoses that are believed to be hemodynamically
significant. However, collateralization in the posterior circulation can be
extensive, and the presence of hemodynamically significant lesions in the
proximal vessels does not necessarily result in diminished posterior circula-
tion blood flow. QMRAmay provide a method of selection for intervention
for those patients with VBD who are most likely to benefit from an open or
endovascular surgical procedure. This article may represent a major step
forward for the selection of patients for vertebral artery reconstruction.
Cilostazol Prevents the Progression of Symptomatic Intracranial Arterial
Stenosis: The Multicenter Double-Blind Placebo-Controlled Trial of
Cilostazol in Symptomatic Intracranial Arterial Stenosis
Kwon SU, Jo Y-J, Koo J-S, et al. Stroke 2005;36:782-786.
Conclusion: Cilostazol appears to prevent progression of intercranial
arterial stenoses that have previously been associated with symptoms.
Summary: Cilostazol appears to have a number of pleotrophic effects
other than improvement of intermittent claudication. It has been shown to
decrease restenosis after coronary angioplasty and stenting and reduce
growth rate of carotid intimal medial thickness in patients with diabetes. In
this trial, the authors investigated the ability of Cilostazol to prevent pro-
gression of intercranial arterial stenoses associated with symptoms. The
patients enrolled were 35-80 years of age and had a recent ischemic stroke
within two weeks that was felt to be associated with stenosis in the M1
segment of the middle cerebral artery or stenosis of the basilar artery.
Patients were required to have MRA evidence of stenosis in the noted
arteries as well as acute ischemic changes onMRI. Participants were followed
at 1, 3, 5, and 6 months. Primary outcome was progression of stenosis in
symptomatic vessels at 6 months. Stenosis was classified into 1 of 5 grades
based on MR findings. Progression was defined as worsening of stenosis by
1 or more grades and regression of stenosis was defined as improvement of
stenosis by 1 or more grades compared to the initial MRA study. Patients
were also assessed with transcranial Doppler examinations.
From February 2000, to July 2003, 135 patients were enrolled in the
trial. Sixty-seven were randomly assigned to Cilostazol and 68 assigned to
receive placebo. All patients in both groups also received 100mg of aspirin
daily.
Baseline patient characteristics and location of intercranial lesions re-
sulting in symptoms were similar in the two groups. During follow up there
were no strokes or transient ischemic attacks and two participants in each
group had an acute coronary event. There was one unexplained death in each
group. There were 20 dropouts in the Cilostazol group (29.9%), and 14
dropouts in the placebo group (20.6%).
Progression of a symptomatic intercranial arterial stenosis occurred in 3
of the 45 patients available for follow up in the Cilostazol group (6.7%) and
15 of the 52 patients available for follow up in the placebo group (28.8%).
Regression of the intercranial lesion producing symptoms was noted in
24.4% of the Cilostazol group and 15.4% of the placebo group. Overall
progression of an intercranial arterial stenosis associated with symptoms was
less frequent in the Cilostazol group than the placebo group (p  0.008).
Transcranial Doppler studies also indicated progression to be less frequent in
the Cilostazol group than the placebo group (p 0.001). Progression rates
of intercranial arterial lesions that were not associated with symptoms were
not different between the two groups (p  0.384).
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